Patients with any grade 3 or higher toxicity by tested compound category for phase 1 trials Ν **Proportion** 95%-CI Effect size Antiangiogenesis 8 27.3 (10.1; 55.7)Chemotherapy 7 (32.0; 52.7)42.0 **Immunomodulator** 15 13.1 (7.2; 22.8)Other 10 41.3 (27.0; 57.2)Receptor or signal transduction 48 40.9 (34.8; 47.3)-Vaccine 8 5.3 (2.3; 11.7)Overall 96 33.5 (29.0; 38.4)



< 0.001

100

Effect size (95%–CI)